REVIEW

Recent advances in nanomedicines for the treatment of ischemic stroke

Chao Li, Tao Sun*, Chen Jiang*

Key Laboratory of Smart Drug Delivery, Ministry of Education, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Department of Pharmaceutics, School of Pharmacy, Research Center on Aging and Medicine, Fudan University, Shanghai 201203, China

Received 28 June 2020; received in revised form 27 August 2020; accepted 13 September 2020

Abstract Ischemic stroke is a cerebrovascular disease normally caused by interrupted blood supply to the brain. Ischemia would initiate the cascade reaction consisted of multiple biochemical events in the damaged areas of the brain, where the ischemic cascade eventually leads to cell death and brain infarction. Extensive researches focusing on different stages of the cascade reaction have been conducted with the aim of curing ischemic stroke. However, traditional treatment methods based on antithrombotic therapy and neuroprotective therapy are greatly limited for their poor safety and treatment efficacy. Nanomedicine provides new possibilities for treating stroke as they could improve the pharmacokinetic behavior in vivo, achieve effective drug accumulation at the target site, enhance the therapeutic effect and meanwhile reduce the side effect. In this review, we comprehensively describe the pathophysiology of stroke, traditional treatment strategies and emerging nanomedicines, summarize the barriers and methods for transporting nanomedicine to the lesions, and illustrate the latest progress of nanomedicine in treating...
ischemic stroke, with a view to providing a new feasible path for the treatment of cerebral ischemia.

© 2021 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Stroke is the second leading cause of death and severely affects the daily life of survivals due to its high disability rate. Ischemic stroke normally occurs when a vessel that supplies blood to the brain is blocked, and it makes up approximately 87% of all stroke cases. Ischemia would initiate the ischemic cascade which involves a series of biochemical events, including energy failure, ion imbalance and excitotoxicity, oxidative stress, cell death (apoptosis or necrosis), initiation of the complement system, and exacerbation of the inflammation and immune response. The cascade would eventually lead to irreversible brain damage. Many strategies have been adopted to reconstruct blood supply to the brain, aiming to address the aforementioned harmful effects of ischemia. Thrombolysis with tissue plasminogen activator to realize recanalization to the brain is the gold standard for ischemic stroke treatment. However, the time window of thrombolysis is relatively narrow (≤4.5 h), due to the risk of hemorrhagic transformation (HT) caused by the low targeting ability to thrombus. Thus, only a small number of patients could receive and benefit from the thrombolytic therapy in time. Moreover, restoring blood flow to the ischemic brain would cause secondary reperfusion injury. Reperfusion would exacerbate the production of reactive oxygen species (ROS) and the amplification of inflammation and immune response, which would cause undue neural death, impair the integrity of blood–brain barrier (BBB) and eventually lead to brain edema. There are also numerous preclinical studies focusing on protecting neurons from the injury at different stages of ischemia and reperfusion. However, most neuroprotective agents have unneglectable defects including low solubility, short half-life and poor BBB permeability. It is difficult and costly to find safer and more effective new drugs to treat ischemic stroke. Thus, there is an increasing demand to endow them with pharmaceutical improvement to existing drugs to suit the clinical requirements.

Numerous nanomedicines have been developed to improve the efficacy and to reduce the side effects of traditional treatment methods, since well-designed nanomedicines possess many unique advantages. First, nanomedicine could increase the solubility of poorly soluble drugs, improve the stability and extend the half-lives of drugs in vivo. Second, targeted modified nanomedicine could assist drugs to cross the BBB which is a main barrier for most drugs to reach the brain, and realize accumulation at the desired site to avoid non-specific distribution. Targeted modification could also help the nanomedicine to mainly taken up by specific cells, such as damaged neurons. Hence, nanomedicines with targeting ability could not only increase the therapeutic effect, but also reduce the injected dose and toxicity of drugs. In addition, nanomedicines consisted of different functional materials could control the release of drugs, and the functionalized vehicle might be effective in treating ischemic stroke. Moreover, nanomedicines provide possibilities for some emerging treatments, such as gene therapy, which is favor of recovering from injury at the chronic phase of stroke. Nanomedicines include liposomes, micelles, nanoparticles (NPs), emerging cell membrane coated NPs and exosomes, all of which have been applied in the preclinical studies for treating ischemic stroke. Apart from discussing the pathophysiology of ischemic stroke which might affect the design of nanomedicine, as well as traditional treatment strategies and their deficiencies, this review mainly focuses on investigating the barriers and methods to transporting nanomedicines to the targeting sites and summarizes preclinical studies of nanomedicines for the treatment of ischemic stroke according to various abnormalities at different phases of ischemic cascade.

2. The pathophysiology of ischemic stroke

Understanding the pathological mechanisms of ischemic stroke is helpful in finding therapeutic targets and developing more efficiently targeted nanomedicines. A series of molecular and cellular events are involved in the ischemic cascade, which occur at different time and interconnect with each other. In the ischemic core, hypoperfusion restricts the oxygen/glucose supply to the brain, which causes the energy failure of neurons. Insufficient ATP causes the ion pumps to operate abnormally. As a result, the ion gradient across the cell membrane is out-of-balance. Increased influx of Na⁺ and efflux of K⁺ leads to the depolarization of neurons and glial cells, as well as extracellular accumulation of glutamate that can cause excitotoxicity. Intracellular accumulated Na⁺ and following increased Cl⁻ will result in the swelling of cells, destruction of cell membrane and final necrosis. In the ischemic penumbra, extracellular accumulated glutamate over-activates the glutamate receptors, which leads to the influx of Ca²⁺. Then numerous Ca²⁺-dependent enzymes are activated, including proteases which destroy the cell integrity, nitric oxide synthase (NOS) and enzymes producing ROS. ROS not only directly reacts with macromolecules to cause lipid peroxidation, protein oxidation and DNA damage, but also causes indirect injury through multiple signaling pathways, such as caspase-mediated apoptosis.

Reperfusion would exacerbate the production of ROS and subsequent activation of matrix metalloproteinases (MMPs), which would worsen the damage of neurovascular units. Neurons under stress and necrotic cells would release damage-associated molecular patterns (DAMPs), such as high mobility group protein B1 (HMGB1) and ATP, which would initiate the recruitment of intrinsic microglia and upregulate the expression of pro-inflammatory mediators. Pro-inflammatory mediators such as chemokines and adhesion molecules would drive and promote the infiltration of neutrophils and blood-borne...
macrophages into the ischemic brain. Complement system can be activated in the blood and brain parenchyma as well, which leads to increased leukocytes infiltration. Neutrophils and mononuclear phagocytes recruited to the ischemic brain will contribute to the production of inducible nitric oxide synthase (iNOS), ROS, MMPs and other inflammatory mediators such as tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6) and interleukin-1β (IL-1β), which eventually impairs the BBB permeability and leads to brain edema. The multiple molecular and cellular events that involved in the ischemic cascade are illustrated in Fig. 1.

3. Traditional treatment strategies

Conventional therapy for ischemic stroke mainly includes the employment of antithrombotic drugs to improve the brain blood circulation, and neuroprotectant to protect neurons from death induced by ischemia and reperfusion.

3.1. Antithrombotic drugs

Clinically used antithrombotic drugs are generally classified into antiplatelet and anticoagulant drugs, which are applied to prevent thrombosis, and thrombolytic drugs to dissolve the existed thrombus. Platelets play a vital role in the formation of thrombus, and antiplatelet treatment not only prevents the formation of thrombus, but also reduces the growth of thrombus. For instance, aspirin is the most widely used drug for antiplatelet treatment, as aspirin could selectively inhibit the cyclooxygenase-1 (COX-1) involved in the platelet adhesion at a low dosage without inhibiting the synthesis of prostacyclin. Anticoagulants such as heparins, vitamin K antagonists and argatroban have also been applied for treating ischemic stroke, as they could reduce the formation of secondary blood clots to improve prognosis. In detail, heparins could bind to antithrombin to deactivate thrombin and inhibit clotting factors; vitamin K antagonists, such as warfarin would reduce the production of activated clotting factors; argatroban could directly inhibit thrombin to inhibit the formation of blood clot.

Being different from antiplatelet and anticoagulant drugs, thrombolytic agents could activate plasminogen to form plasmin to degrade the fibrin involved in the thrombus, dissolve the formed clot and restore the blood supply to the ischemic brain. Urokinase and alteplase are inherent plasminogen activators in vivo. As alteplase could initiate the fibrin-specific fibrinolytic process, it is more widely applied clinically than urokinase. Many new plasminogen activators with improved fibrin specificity and prolonged half-life have been developed, such as desmoteplase and tenecteplase.

3.2. Neuroprotective agents

Neuroprotective agents could act on different pathophysiological pathways involved in ischemic cascade, and thus exert neuroprotective effects at different stages of stroke. One main
the influx of Ca^{2+}. Memantine, an N-methyl-D-aspartate receptor (NMDAR) antagonist, is able to reduce the lesion volume without interfering with the normal physiological function of NMDAR. Another method to reduce the deleterious effects of excitotoxicity is regulating downstream signaling pathways activated by glutamate, such as the influx of Ca^{2+}. Nimodipine is a calcium channel blocker, and it could realize limited neuroprotective effects in preclinical models. Eliminating oxidative stress is also a potential treatment strategy to rescue ischemic neurons. Edaravone is a free radical scavenger and able to inhibit lipid peroxidation, which has shown significant neuroprotective effect in clinical trials.

Moreover, current research mainly focused on attenuating the immune-mediated inflammatory response during the acute phase of ischemic stroke. Neutrophils play an important role in the occurrence and development of inflammation, treatment with antibody against E-selectin could reduce the infiltration of neutrophils into the ischemic brain and realize reduction in the infarct volume. Fingolimod is an immunosuppressant that restricts lymphocytes migration from lymph nodes and reduces their infiltration into the brain. Administration of fingolimod could significantly reduce the infarct volume and decrease the BBB permeability, and improve the neurological function of patients.

The application of anti-inflammation agents and immunosuppressant reveals a new strategy for neuroprotection, yet the clinical application of neuroprotectant is still not optimistic. Table 1 summarizes the types of traditional treatment strategies, representative therapeutic agents and their molecular and cellular targets.

### 3.3. Deficiencies of traditional treatment strategies

Although some antithrombotic drugs and neuroprotectant have been used clinically, there are still some problems needed to be resolved to obtain safer and more effective therapeutic agents. For most antithrombotic drugs, the non-specific distribution and low thrombus targeting efficiency would increase the risk of bleeding in patients. Anticoagulant therapy could reduce the recurrence rate of ischemia during acute phase of stroke, but the benefit is often offset by the increase in symptomatic intracranial hemorrhage. The effect of thrombolysis with plasminogen activator is also limited, since the circulation time of thrombolytic proteins is relatively short in vivo due to the clearance of proteinase, and the use of thrombolytics would increase the risk of bleeding. For instance, alteplase might amplify the role of MMPs while dissolving the thrombus, and thereby destroys the intercellular matrix of the BBB and increases the probability of intracerebral hemorrhage.

There are also some deficiencies in neuroprotective treatment. Most neuroprotectant showed limited effects in treating ischemic stroke for their short half-lives, potential toxicity, poor specificity of distribution, as well as low targeting efficiency to cross the BBB to achieve effective drug accumulation at the aimed lesions. For instance, the half-life of edaravone in vivo is as short as 5.4 min, which seriously hinders the effectiveness of the agent. In addition, biological macromolecules such as superoxide dismutase (SOD) which could efficiently eliminate ROS, and cyclosporine A (CsA) which could inhibit the inflammatory response, have exhibited fine protective effect on damaged neurons. However, these protein or peptide drugs also possess poor stability and short half-lives in vivo, and extremely low capability in crossing the BBB. Moreover, gene medicines could also be applied for treating stroke, however, it would also encounter the plight of protein or peptide drugs. If these neuroprotectant could be successfully delivered to the ischemic brain, these therapeutic molecules are hopeful to play a more effective and lasting protective role.

Currently, in the absence of more effective drugs in treating ischemic stroke, it is necessary to devote pharmaceutical improvements to existing drugs to prolong their half-life in vivo, meanwhile, to decrease their non-specific distribution in non-targeting tissues, and to improve their targeting ability to brain lesions to obtain better results. Thus, there is a great demand in developing more efficient and safer delivery strategy of antithrombotic drugs and neuroprotectant for ischemic stroke treatment.

### 4. Barriers in targeted drug delivery to the damaged brain

The ideal targeted nanomedicine for cerebral ischemia treatment is regarded to be able to deliver drugs to thrombus site or the damaged brain parenchyma effectively, and further to specific cells, such as neurons or glial cells. For therapy with neuroprotectant, although intracranial or intrathecal injection could obtain greater benefits sometimes, their unsustainable drug concentration and invasiveness limits their long-term application, and systemic administration is a more practical method in most cases. Once the nanomedicines enter the blood, they tend to protect the loaded drug from the enzyme degradation; the relatively particle with higher size of nanomedicines could also prevent the drug from being quickly eliminated by the kidney. However,

| Table 1 | Summary of traditional treatment strategies. |
|---------|---------------------------------------------|
| Type of drugs | Therapeutic agent | Mechanism of action | Ref. |
| Antiplatelet drugs | Aspirin | Selectively inhibits the COX-1 involved in platelet adhesion | 40 |
| Anticoagulants | Heparins | Bind to antithrombin to deactivate thrombin and inhibit clotting factors | 41 |
| | Warfarin | Vitamin K antagonist, reduces the production of activated clotting factors | 41 |
| | Argatroban | Directly Inhibits the thrombin | 41 |
| Thrombolytics | Urokinase and alteplase | Activate the plasminogen to form plasmin | 42 |
| Neuroprotectant | Memantine | NMDAR antagonist | 45 |
| | Nimodipine | Calcium channel blocker | 46 |
| | Edaravone | Free radical scavenger | 47, 48 |
| | Antibody against E-selectin | Limits the infiltration of neutrophils into the ischemic brain | 49 |
| | Fingolimod | Reduces the infiltration of lymphocytes into the damaged brain | 50 |
nanomedicines with larger size might be opsonized by plasma proteins and subsequently phagocytosed by the reticuloendothelial system (RES), resulting in non-targeted accumulation in liver and spleen. PEGylation could help the nanomedicines to evade the phagocytosis, achieve longer circulation period in the blood, and reduce its non-specific distribution\(^{-57}\). PEG would generate hydrophilic sheath on the surface of NPs to shield the opsonization of opsonin and reduce the phagocytosis of macrophages. Longer circulation time is required for nanomedicine delivery, which can increase the chance of nanomedicine of leaking into the brain through the damaged BBB, as well as provide more opportunities for targeting ligands to combine with receptors or transporters. In this section, we will mainly discuss the obstacles and strategies that the neuroprotective nanomedicines encounter before they penetrate into the brain parenchyma across the BBB. Thrombus targeting strategies for thrombolitics-loaded nanomedicine are discussed in Section 5.1.

### 4.1. BBB

BBB is a special and inherent structure between the brain tissue and blood. It is mainly composed of brain capillary endothelial cells and their tight junctions (TJs), pericytes embedded in capillary basement membrane, and astrocytes end-feet around the capillary (Fig. 2). While restricting the entry of toxic substances into the central nervous system, the BBB also prevents almost all macromolecular drugs and nearly 98% of small molecule drugs from entering the brain tissue. It is difficult for nanomedicines to cross the tight BBB; fortunately, there are strategies that could be adopted to help nanomedicine go cross the BBB and diffuse into the brain parenchyma.

### 4.2. Strategies for nanomedicines to cross the BBB

#### 4.2.1. BBB disruption and modulation

It is reported that the structure of BBB is partially destroyed during the occurrence of stroke\(^{-58,59}\). Subsequently, the permeability of BBB to molecules or particles increases, which provides more possibilities for nanomedicine without targeted modification to enter the brain parenchyma. In the early stage, the upregulated expression of caveolin in endothelial cells would enhance the paracellular transport of nanomedicine; the following breakdown of TJs will promote the particles to cross the BBB via the paracellular route\(^{-59}\). There were many unmodified nanomedicines which achieved passive accumulation in brain through the disrupted BBB after stroke\(^{-53,55,56,57}\).

However, the disruption of BBB is not obvious in the first few hours after the ischemic attack, and this period coincides with the treatment window\(^{-57}\). Moreover, the crossing of compromised BBB in stroke is often not sufficient for nanomedicines to achieve therapeutically drug concentration. Modifying vehicles with targeting ligand could assist them to cross the intact BBB through receptor-mediated transcytosis as discussed in section 4.2.2.

Recently, some studies adopted BBB modulators to boost the crossing efficiency. The more researched modulators are adenose 2 A receptor (A2AR) agonist, which bind to the A2AR over-expressed on the luminal and abluminal side of cerebral capillaries during stroke\(^{-58,71,72}\), such as lexiscan, purine nucleotide derivative CGS21680. Activating A2AR could temporally improve the BBB permeability by actively opening the TJs, subsequently helps nanomedicine achieve effective accumulation in the ischemic brain. For instance, edaravone-loaded PEG-PLA micelles were anchored with CGS21680, which acted as both a targeting and signaling molecule, and this strategy simultaneously increases the paracellular transport and receptor-mediated transcellular transport of the nanomedicines\(^{-71}\). In another study, Lexiscan and an apoptosis inhibitor were co-encapsulated in PEG-PLGA-NPs modified with targeting ligand chlorotoxin. NPs released lexiscan after entering the ischemic site via the damaged BBB, which in turn momentarily improve the BBB permeability to promote the entry of more NPs\(^{-58}\).

#### 4.2.2. Ligand-based targeting

Numerous receptors and transporters are highly expressed on brain capillary endothelial cells to transport glucose, amino acids, proteins, and other nutrients to maintain brain homeostasis\(^{-73}\). Modifying nanomedicines with aforementioned endogenous ligands or exogenous derivatives could help them cross the BBB actively via receptor- or transporter-mediated transcytosis. The studied receptors and transporters mainly include transferrin receptor (TfR), low-density lipoprotein receptor (LDLR) and nicotinic acetylcholine receptor (nAChR). There are also some receptors highly expressed after ischemia and reperfusion, which provides more opportunities for targeted delivery of nanomedicines. In addition to covalently conjugating ligands to nanomedicine, NPs can also achieve active targeting by adsorbing endogenous ligands in the blood. For instance, puercarin-loaded PBCA NPs were coated with polysorbate 80 which could adsorb apolipoprotein E (APOE) in blood. This method enhanced the accumulation of NPs in brain via the interaction between APOE and LDLR-related protein (LRP)\(^{-74}\). The ligands corresponding to the receptors and their applications in targeted delivery by nanomedicines are summarized in Table 2\(^{-78,71,74-88}\).

#### 4.2.3. Biomimetic targeting

Targeted nanomedicines have shown broad applying prospects in treating stroke, though due to the characteristics of exogenous nanomaterials, there is still a risk of being recognized and cleared by the RES. Recently, the bionic nanomedicine delivery strategies based on live cells, cell membrane vesicles and exosomes have been widely researched. Encapsulating nanomedicine onto live
Exosomes are cell membrane vesicles with nanoscale, which can also be used for targeted drug delivery since they retain the membrane protein of the original cells \(^{52,91}\). Further targeted modification of cell membrane vesicles and exosomes could improve their targeting ability \(^{45,75,80,81,83}\). For instance, cRGD-modified mesenchymal stromal cell (MSC)-derived exosomes loading with curcumin accumulated more at the lesion area, compared to unmodified exosomes, as surface modification improved the active targeting ability of exosomes \(^{81}\).

### 4.2.4. Adsorptive-mediated transcytosis

Electrostatic interactions between cationic protein/cell penetrating peptide (CPP) with positive charge and brain capillary endothelial cells with negative charge could assist nanomedicine to cross the BBB through adsorptive-mediated transcytosis (AMT). For instance, modification with TAT (belonging to the CPP family) improved the ability of nanoplatelets crossing the BBB to deliver loaded drug \(^{94}\). In another research, cationic bovine serum albumin conjugated tanshinone PEG-PLA NPs possessed the ability to attach to the negatively charged brain microvascular lumen sides, and increased the amount of tanshinone in the ischemic brain through AMT \(^{75}\).

### 4.2.5. Bypass the BBB

In addition to highly invasive intracranial and intrathecal injections, intranasal administration provides a new and feasible route to bypass the BBB. Intranasal administration can mainly deliver nanomedicine to the olfactory bulb or other brain regions through the olfactory nerve. For instance, curcumin-loaded embryonic stem cell exosomes delivered drug into brain intra-nasally, which decreased the level of ROS and infarct volume \(^{96}\). In addition, the positively charged vehicle could increase the penetration of nanomedicine into nasal epithelial cells to enhance the transport of drugs to the brain. Arginine-poly-amidoamine ester (e-PAM-R), a biodegradable polycationic ester, was selected to carry anti-HMGB1 siRNA intranasally to improve the delivery efficiency of siRNA \(^{97}\).

### 5. Nanomedicines for stroke treatment

#### 5.1. Nanomedicines improving the efficacy and safety of thrombolytics

There will be more serious and rapid damage in the ischemic core where the blood flow is lowest within the ischemic regions \(^{13}\), the cells in ischemic core are doomed to die regardless of any treatments, unless blood supply recovers rapidly. In the ischemic penumbra which is at the edge of the ischemic core, neuronal injury develops slowly due to the existence of microcirculation which is an adjacent capillary network that maintains brain perfusion above the threshold of immediate cell death \(^{13}\). Early reperfusion is the main goal of most interventions to ensure cells in penumbra resistant to the ischemia-induced death. However, the effect of thrombolysis with plasminogen activator is limited, for their short half-life and low targeting efficiency. As expected, nanomedicines have been developed to deliver thrombolytics efficiently and precisely via physical targeting, ligand-mediated active targeting and biomimetic targeting. Moreover, the well-designed response release further improves the effectiveness and safety of delivering thrombolytics with nanocarriers.
5.1.1. Physical targeting
Physical targeting refers to guiding NPs to the target site with the assistance of external manipulation, or enabling the response release of drug from nanomedicine at the target site under the action of heat or mechanical force such as ultrasound. PEG crossed glycol chitosan soft NPs with good ultrasound response ability were synthesized to deliver urokinase\(^9\)\(^9\)\(^1\)\(^0\), NPs achieved better effect in degrading clots and protecting the BBB, though NPs did not decrease the risk of HT than free protein.

5.1.2. Ligand-mediated active targeting
Modifying vehicle with specific ligand could also confer the targeting ability on thrombolytics. As the fibrin is a major component of thrombus, anti-fibrin antibody-modified polystyrene NPs were applied to deliver alteplase through conjugating proteins on the surface of NPs. Alteplase NPs showed much less activity than free enzyme in the absence of embolus, which would reduce the unspecific cleavage of plasminogen and further decrease the risk of bleeding\(^1\)\(^0\). Glycoprotein IIb/IIIa (GPIIb/IIIa) receptors on platelet membrane may play a key role in the aggregation of platelets and the formation of thrombus, cyclic Arg-Gly-Asp (cRGD) peptide which could specifically bind the GPIIb/IIIa receptors is employed to mediate targeting thrombolysis, such as cRGD-modified target sensitive streptokinase (SK) liposomes\(^1\)\(^0\)\(^2\)\(^–\)\(^1\)\(^0\)\(^4\). After the interactions between cRGD with activated platelets liposomes consisted of cRGD-palmitic acid underwent destabilization and released encapsulated SK around the clot\(^1\)\(^0\)\(^2\).

Apart from single-targeted ligand modification, there are some studies on dual ligand-modified nanomedicine with higher targeting efficiency\(^1\)\(^0\)\(^5\). The overexpressed P-selectin on activated platelets mediate the interaction between thrombocytes. Inspired from this mechanism, dual-targeted nanovesicles modified with cRGD and P-selectin targeting peptide were developed to deliver SK\(^1\)\(^0\)\(^5\). Nanovesicles composed of glycerophospholipids achieved stimuli-responsive release of drugs after locating at the target site, as glycerophospholipids could be cleaved by phospholipase A2 which is overproduced by activated platelets and leukocytes in thrombus\(^1\)\(^0\)\(^5\) (Fig. 3). Nanovesicles showed better therapeutic effects, and the risk of bleeding was reduced compared to free drug.

5.1.3. Biomimetic targeting
Considering the role of platelets in thrombus formation, bio-engineered nanoplatelets were developed for treating ischemic stroke. The polymeric NP core was coated with platelets membrane, the membrane was conjugated with TAT-peptide-coupled alteplase linked with amino acid sequences which could be cleaved by thrombin\(^1\)\(^0\)\(^4\). The nanoplatelets can avoid the recognition and phagocytosis of the RES, and adhere to the thrombus site to prolong the retention of NPs and achieve responsive release of alteplase. Biomimetic targeting nanomedicines based on cell membrane have become an emerging effective strategy in treating ischemic stroke.

In conclusion, targeted delivery of plasminogen activator via nanomedicine could increase the accumulation of drugs at the thrombus site, thereby reducing the dosage and minimizing the side effects of thrombolytics. The strategies, including

![Figure 3](https://example.com/f3.png)

**Figure 3** Schematic diagram of targeted thrombolysis using nanovesicles inspired from activated platelets. (a) Nanovesicles bind the activated platelets in thrombus through the interaction between RGD and GPIIb-IIIa, as well as P-selectin targeting peptide and P-selectin. (b) Nanovesicles composed of glycerophospholipids achieve responsive release of drugs after locating at the target site, as the glycerophospholipids are cleaved by phospholipase A2 overproduced by activated platelets and leukocytes in thrombus. (c) Drug released from degraded nanovesicle realizes targeted fibrinolysis. PMINs: platelet microparticle-inspired nanovesicles. Reprinted with the permission from Ref. 105. Copyright © 2017, Elsevier Ltd.
achievement and limitation in targeted delivery of thrombolytics are summarized in Table 3.

Table 3 Summary of targeted delivery of thrombolytics with nanomedicines.

| Strategy                        | Target | Ligand                   | Nanomedicine                  | Achievement                                                                 | Limitation                              | Ref.          |
|---------------------------------|--------|--------------------------|-------------------------------|----------------------------------------------------------------------------|------------------------------------------|--------------|
| Physical targeting              |        |                          | Urokinase-loaded NPs          | Enhanced clots degradation and BBB protection                              | No reduction in the risk of HT          |              |
| Ligand-mediated active targeting|        | Anti-fibrin antibody      | Alteplase-loaded NPs          | Showed less activity in the absence of embolus                             | Lack of experimental data in vivo       |              |
| GPIIb/IIIa receptors            |        | cRGD peptide             | Target sensitive SK-loaded liposomes | Target sensitive release of SK; enhanced clot dissolution in vivo | No data about the risk of HT           | 101          |
| Biomimetic targeting            |        | Membrane proteins on platelets | Alteplase-loaded NPs coated with platelets membrane | Achieved responsive response of alteplase in thrombus | No data about the risk of cerebral hemorrhage | 94           |

5.2. Nanomedicines delivering oxygen to the ischemic brain

For patients who are not suitable for thrombolysis or have shown microcirculation impairment due to the formation of microthrombus, delivering sufficient O2 to the ischemic penumbra is a potential method. Hemoglobin (Hb) is a natural O2 carrier, but short half-life and hypertension response limit its clinical application. Liposomal Hb (LHb) could not only prolong the circulation time of Hb in vivo, but also deliver sufficient O2 to cross the obstacles in the microcirculation and get to the penumbra where red blood cells (RBCs) can seldom reach. In a rat thrombosis model induced by photochemistry, fluorescein-labeled RBCs were mainly observed in larger vessels, whereas fluorescent liposomes filled all vessels including capillaries in a manner similar to plasma. LHb significantly reduced the infarct volume of ischemic penumbra, compared to free Hb and homologous blood which contains lots of RBCs carrying Hb. Moreover, LHb can also significantly attenuate the infarction size in transient ischemic model when infused immediately after the middle cerebral artery occlusion (MCAO). Though delivering O2 could rescue dying neurons by relieving hypoxia in the penumbra, too much O2 after reperfusion may cause the significant increase in ROS, the timing and dosage of administration need further investigation.

5.3. Nanomedicines regulating ion imbalance and excitotoxicity

Ion imbalance and excitotoxicity occur upstream during the ischemic cascade, and regulating the progression of these events is expected to inhibit the amplification of damage in the early stage of stroke as well as produce more effective intervention outcomes. The sulfonyleurea receptor 1-transient receptor potential melastatin-4 (SUR1–TRPM4) complex is a nonselective cation channel which is sensitive to ATP, and the expression of the channel is upregulated in ischemic neurons, astrocytes and capillaries. Depletion of ATP in the ischemic brain leads to the continued opening of SUR1-TRPM4 channel which increases the influx of Na+, causes the depolarization of cells and cytotoxic edema, and finally leads to the necrocytosis and brain swelling. Glyburide is an inhibitor of SUR1–TRPM4 complex, and has shown treating effect in reducing edema and infract volume in animal and human. However, glyburide is a substrate for P-glycoprotein, which limits its ability in penetrating the BBB to realize the effective therapeutic concentration. As expected, several nanomedicines have been developed to deliver glyburide, such as poly (L-lactide-co-glycolide) nanoparticles (PLGA-NPs), thrombin-responsive size-shrinkable brain targeting NPs, glyburide-loaded betulinic acid NPs. It has been reported that neural stem cells (NSCs) could migrate to the injured site due to the interaction between C-X-C chemokine receptor type 4 (CXCR-4) and ligand stromal cell-derived factor-1 (SDF-1) which is overexpressed in the ischemic brain. PLGA-NPs coated with membrane derived from NSCs overexpressed CXCR4 demonstrated higher effects in enhancing brain targeting delivery of glyburide, which significantly reduced the infract volume. Thrombin-responsive NPs could shrink their size after crossing the damaged BBB and arriving at the ischemic site where thrombin is highly expressed, which enhanced the penetration of NPs in the brain parenchyma. Betulinic acid NPs realized penetrating the ischemic brain through the interaction between betulinic acid and cannabinoid receptor one overexpressed on the damaged BBB, which can improve the delivery efficacy of glyburide to the brain.

Postsynaptic density protein-95 (PSD-95) participates in the activation of neuron nitric oxide synthase (nNOS) mediated by NMDAR via the formation of NMDAR/PSD-95/nNOS complex, disrupting the association between nNOS and PSD-95 provides a method to ameliorate the damage caused by excitotoxicity. ZL006 could block the nNOS-PSD-95 interaction selectively, however, the drug has obvious drawbacks in the ability to accumulate in the ischemic brain. Dual targeted liposomes conjugated with T7 peptide and stroke-homing peptide (SHp) were developed to deliver ZL006 accurately, and T7 peptide could help the liposomes transport across the BBB through TIR-mediated...
transcytosis\textsuperscript{24,117}, SHp preferentially homed to the ischemic territory and mediated the endocytosis of liposomes by damaged neurons via glutamate receptors\textsuperscript{79}. Dual targeted liposome could significantly reduce the infarct volume, and improve neurological outcomes in stroke rats, compared with T7 peptide or SHp-modified liposomes. In another research, dextran NPs coated with RBCs membrane modified with SHp were developed to deliver NR2B\textsuperscript{9c} peptide which could prevent the binding of PSD-95 to NMDAR to reduce the excitotoxicity induced by glutamate\textsuperscript{80}.

Tacrolimus could inhibit the activation of Ca\textsuperscript{2+}-dependent calcineurin through binding the tacrolimus-binding protein in neurons. However, frequent use of high-dose tacrolimus to achieve good therapeutic effect has shown side effects\textsuperscript{118}. Liposomal tacrolimus can improve the solubility of drug, and reduce the administration dosage without affecting the neuroprotective efficacy, as liposomal drug diffused more into the ischemic brain than free drugs through the damaged BBB\textsuperscript{60}. Table 4 summarizes the strategies in targeted delivery of nanomedicines which could deliver oxygen, regulate ion imbalance and excitotoxicity.

5.4. Nanomedicines reducing oxidative stress

Therapy employing antioxidants to scavenge excessive ROS, not only attenuates the oxidative stress injury, but also reduces downstream apoptosis and inflammatory responses. Therefore, antioxidant therapy now is a major method to treat injury caused by the ischemia and reperfusion. Antioxidants in preclinical research mainly include small molecule compounds, antioxidant

Figure 4  (A) Scheme of targeted delivery of PLGA NPs coated with membrane derived from NSCs which overexpressed CXCR4 to the ischemic brain. Lentiviral transduction was applied to transform NSCs to overexpress CXCR4. PLGA NPs accumulate in the ischemic area after intravenous injection, and glyburide entrapped in NPs are released to rescue neurons. (B) The accumulation of IR-780-loaded NPs in ischemic brain (n = 3), CMNPs showed significantly higher accumulation than MNPs or NPs. (C) Infarct volume (n = 5), of MCAO mice treated with different formulations. CMNPs: CXCR4-overexpressing membrane-coated NPs; Gly: glyburide; MNPs: membrane-coated NPs. Reprinted with the permission from Ref. 75. Copyright © 2019, WILEY-VCH.
and inorganic materials. Nanomedicines could improve the pharmacokinetic performance of antioxidants, and assist them to cross the BBB to accumulate at the damaged brain.

Many small molecule antioxidants are plant-derived phenolic and keto compounds, which could react with ROS, such as baicalin, luteolin, curcumin, resveratrol, tanshinone, and puerarin. However, the poor solubility, short half-life, and limited BBB penetrability restrict their application. Nanotechnology-based delivery strategies have been developed to solve these problems, such as resveratrol albumin NPs, cationic NPs, PLGA-NPs coated with NSCs membrane that highly expressed CXCR4, and PEG-PLA micelles modified with CGS21680. TEMPO-contained micelles significantly reduced the ROS level in the damaged brain, reduce the area of infarct, and attenuate the breakdown of neurovascular units.

In addition to natural antioxidants derived from plant, there are also many synthetic small molecule antioxidants, such as edaravone, nitroxyl radicals, PEG-PLA micelles modified with CGS21680, and the BBM modulation strategy could help the edaravone micelles realize more effective accumulation in the ischemic brain and rescue more neurons. As a nitroxyl radical, TEMPO is found to be quickly reduced by antioxidant in vivo, and administration with TEMPO might induce hypotension. PH-Sensitive PEG-poly-chloromethylstyrene (PEG-b-PCS) micelles were designed to convert TEMPOs via the amination with 4-amino-TEMPO, and the micelles would decompose and expose the TEMPO upon the protonation of amino groups in intracellular acidic compartments. TEMPO-contained micelles significantly reduced the production of ROS in the ischemic area, and limited the BBB damage.

In some cases, the polymers that construct the nanomedicines could also scavenge the ROS and preserve the damaged neurons, such as ROS-sensitive phenylboronic ester-contained polymers in micelles and NPs, nanomedicines would collapse and simultaneously release the encapsulated drug when eliminating the
high-level ROS. In an interesting study, melanin, a heterogeneous biological polymer, itself can form highly water-dispersible NPs which have the capability against multiple ROS. Coincidentally, betulinic acid NPs also exhibited antioxidant capacity to reduce the oxidative stress and infarct volume in a dose-dependent manner.

SOD can convert superoxide anion to less toxic H2O2, catalase (CAT) can convert H2O2 to H2O and O2, and MCAO mice that overexpresses SOD or CAT showed less injury after reperfusion. However, the short half-life and low BBB penetrability greatly limit the application of exogenous antioxidants for stroke treatment. Liposomes, PBCA NPs, and PLGA-NPs extended the half-life of SOD, and the biphasic opening of the BBB after reperfusion helped them achieve enhanced accumulation of SOD in the ischemic brain. Modification with anti-NMDAR1 antibody helped liposomes and NPs realize enhanced uptake by neurons, which showed significant improvement in reducing the level of oxidative stress and infarct volume, compared to non-targeted nanomedicines and free SOD. In addition, rats receiving PLGA-NPs loaded with CAT and SOD independently after reperfusion showed less infiltrated neutrophils and caspase-3 positive cells in the brain than animals receiving alteplase alone, as reducing oxidative stress is beneficial to inhibit the downstream cascade reaction. Moreover, targeting inflammatory cells circulating in blood mentioned above provides new ideas for targeted delivery of antioxidants.

Ceria nanoparticles (Ce-NPs) which possess the ability to scavenge multiple ROS were applied to treat ischemic stroke. Though the size of Ce-NPs was about 20 nm, the concentration of ceria in non-ischemic brain was low. However, there was significant improvement in the concentration of Ce-NPs in the ischemic brain, as the BBB was damaged after ischemia. In order to realize better treatment, PEGylated Ce-NPs was conjugated with biotinylated-LXW7, targeted modified Ce-NPs could cross the BBB through the interactions between LXW7 and αvβ3 which is upregulated on BBB after stroke, Ce-NPs modified with LXW7 exhibited better effects in reducing infarction size and the degree of BBB breakdown than Ce-NPs. In another study, PEGylated Ce-NPs modified with angiopoietin-2 were used to load edaravone through van der Waals forces, modified Ce-NPs accumulated in the brain tissue via the LR1P1-mediated transcytosis. Edaravone-loaded Ce-NPs exerted synergistic antioxidant effect to rescue damaged neurons, and protected BBB from further damage. Inorganic NPs which have good uniformity are easy to prepare and modify, and have been gradually applied in the field of treatment and drug delivery, though their biosafety still needs further serious investigation. Table 5 summarizes the strategies in targeted delivery of nanomedicines in reducing oxidative stress.

5.5. Nanomedicine reducing apoptosis

Apoptosis is an intermediate event of the ischemic cascade. Reducing apoptosis could not only rescue the stressed neurons, but also weaken the downstream inflammation and immune response, which is conducive to inhibit the deterioration of stroke. Most of the antioxidants mentioned above also have anti-apoptotic ability, as oxidative stress is a main cause of apoptosis. Additionally, the more researched anti-apoptotic drugs are mainly biomacromolecules, and ligand-modified NPs and exosomes have been developed to deliver these drugs. Asialo-erythropoietin (AEPO) could bind the erythropoietin receptor expressed on neurons, and protect the neurons from apoptosis via the activation of protein kinase Akt-1/protein kinase B and extracellular signal-regulated kinases. PEGylated liposomes could prolong the circulation period of AEPO, and the interactions between AEPO and erythropoietin receptor conferred the neuron targeting ability of liposomes upon crossing the damaged BBB. There was more accumulation and retention of I-125-labeled AEPO-liposome in the ischemic hemisphere, in rats which were injected with free AEPO or liposomal AEPO. A single injection of AEPO-liposomes significantly inhibited neuronal apoptosis and improved neurological outcomes, compared to administration of free AEPO. Moreover, anti-apoptosis protein BCL-2 could prevent the caspase apoptosis cascade, pigment epithelium-derived factor is believed to protect neurons from apoptosis through activation of ERK1/2 and induction of BCL-2. For instance, exosomes origin from adipose-derived mesenchymal stem cells which can overexpress pigment epithelium-derived factor could reduce brain damage by inhibiting neuronal apoptosis. In another study, Nogo-66 receptor antagonist Nogo extracellular peptide 1–40 could reduce the increased caspase-3 activity in ischemic brain, and the peptide encapsulated in PLGA-NPs modified with targeting ligand chlorotoxin significantly reduced the infarct volume and enhanced the survival of ischemic mice, compared with free drug. Table 6 summarizes the strategies in targeted delivery of nanomedicines in reducing apoptosis.

5.6. Nanomedicines regulating inflammation and immune response

In the ischemic brain, injured cells can release DAMPs which would activate the innate immunity and initiate the process of inflammatory response. For instance, HMGB1 activates pattern recognition receptors on microglia, which will upregulate the expression of pro-inflammatory gene through multiple signaling pathways, such as the transcription factor nuclear factor-κB (NF-κB) and chemokines. Numerous inflammatory mediators are NF-κB-dependent, such as ICAM-1, IL-2,6, TNF-α and chemokines. NF-κB could also be activated by ROS or cytokines like TNF-α, IL-2, and IL-6. In addition, pattern recognition receptors are also found in the cerebral endothelium, astrocytes and neurons. The inflammatory mediators released from the brain cells might spread to the blood vessels to amplify the expression of inflammatory mediators, which drives the infiltration of leukocytes into the ischemic brain and aggravate the progress of inflammatory response. The inflammatory and immune responses would dramatically expand the brain damage, and curbing the occurrence and progression of inflammation is particularly important for protecting the damaged brain. In addition to inhibiting the upstream events of the ischemic cascade, inhibiting vital components in the inflammatory response, such as pro-inflammatory mediators and cells, could also exert anti-inflammatory effects.

5.6.1. Nanomedicines inhibiting pro-inflammatory mediators

As HMGB1 plays an important role in inflammatory response, inhibiting the production of HMGB1 might be an effective way to reduce the injury caused by inflammation. Gene silencing mediated by RNA interference technology could regulate the specific protein functions, yet the delivery of small interfering
Table 5  The strategies, including achievements and limitations in targeted delivery of nanomedicines in reducing oxidative stress.

| Phase of cascade | Target | Nanomedicine and intervention strategy | Achievement | Limitation | Ref. |
|------------------|--------|----------------------------------------|-------------|-----------|------|
| Oxidative stress | Small molecule antioxidants | Passively | Curcumin-loaded PLGA NPs | Prevented neurons from oxidative damage | No experimental data in vivo | 121,122 |
| | | Passively | Curcumin-loaded PEG-PLA NPs | Protected the BBB against oxidative stress; ameliorated neuronal apoptosis and the release of inflammatory mediators. | Conjugating with targeting ligand might further improve the treatment effect | 62 |
| | Bypass the BBB | | Curcumin-loaded embryonic stem cell exosomes | Delivered drug into brain intranasally, decreased the level of ROS | The safety of nasal administration has not been investigated | 96 |
| | Integrin αvβ3 | | Curcumin-loaded exosomes modified with cRGD | Downregulated activated microglia and the expression of inflammatory cytokines | | 81 |
| | Passively | Resveratrol-loaded albumin NPs | Reduced oxidative stress and the apoptosis of neurons | Passive targeting might not be suitable for long-term administration | 61 |
| | | | | | |
| AMT | Tanshinone-loaded PEG-PLA NPs conjugated with cationic BSA | | Inhibited the inflammatory cascades | There is risks of being phagocytized by the RES | 95 |
| | Passively | Baicalin-loaded liposomes | Improved the accumulation of drug in the ischemic brain | Non-PEGylated liposomes were mainly phagocytized by the RES | 63 |
| | Passively | Luteolin-loaded PEG-PLGA micelles | Inhibited oxidative stress and decreased the release of inflammatory mediators | Targeting efficiency might need further improvement | 64 |
| | | | | | |
| | | | | | |
| LRP | Puerarin-loaded PBCA NPs coated with polysorbate 80 | | Reduced the infarct volume | | 74 |
| | | | | | |
| A2AR BBB modulation | Edaravone-loaded PEG-PLA micelles modified with CGS21680 | | Exerted a more persistent ROS eliminating effect and rescued more neurons | The safety of BBB modulator needs further study | 71 |
| | Passively | PEG-b-PCMS-TEMPO micelles | Suppressed oxidative stress and apoptosis, protected neurovascular units | The study did not reveal the effect and toxicity of NPs in subacute phase | 65,66 |
| | Passively | Melanin-loaded NPs conjugated with PEG | Showed antioxidative effects against multiple RONS, suppressed the expression of inflammatory cytokines | The potential toxicity of the degradation byproducts of PEG-MeNPs needs further investigation | 67 |
| Antioxidase | NMDAR1 | SOD-loaded liposomes, PBCA NPs, and PLGA-NPs; nanomedicines were modified with anti-NMDAR1 antibody | Reduced the oxidative stress and apoptosis, and inhibited the release of inflammatory mediators | The effect of administration in subacute phase is not satisfactory | 82 |
| | Passively | CAT/SOD-loaded PLGA-NPs | Mitigated apoptosis and inflammatory response; promoted neurogenesis | Carotid injection is not conducive to long-term administration | 68 |
| | Biomimetic targeting | PEG-DGL-CAT NPs decorated with PGP, which could hitchhike the circulating neutrophils | Reduced the infarct volume via anti-oxidative effect | The fate of NPs in neutrophils needs further investigation | 91 |
| | Inorganics | Passively | PEGylated ceria NPs | Scavenged ROS and reduced apoptosis | Targeting ability need further improvement | 69 |
| | | | | | |
| | Integrin αvβ3 | | PEGylated Ce-NPs conjugated with biotinylated-LXW7 | Showed better effects in mitigating the oxidative stress and apoptosis | There was no improvement in neurological function | 83 |
| | LRP | Edaravone-loaded Ce-NPs modified with angioprep-2 | Exerted synergistic ROS scavenging ability | | 84 |

A2AR, adenosine 2A receptor; BSA, bovine serum albumin; LRP, lipoprotein receptor-related protein; RONS, reactive oxygen and nitrogen species.
RNA (siRNA) in vivo limits the therapeutic application of this technology. Arginine-poly-amidoamine ester (e-PAM-R) was chosen as the carrier to improve the delivery and transfection efficiency of anti-HMGB1 siRNA. The transfection efficiency of e-PAM-R/siRNA complex was thus improved, as reverse transcription-polymerase chain reaction revealed that there was significant downregulation of HMGB1 mRNA levels in primary cortical cultures treated with NMDA or H2O2, and treatment with e-PAM-R/siRNA reduced the neuronal death. E-PAM-R can successfully deliver siRNA into the brain cells, since there was notable reduction in HMGB1 level and infarct volume after intranasal delivery of e-PAM-R/siRNA in stroke rats.

In addition to HMGB1, TNF-α is also an important inflammatory mediator. CsA is a hydrophobic peptide consisting of 11 amino acid residues, which could inhibit the release of TNF-α and IL-1, and exert anti-inflammatory and neuroprotective activities. However, CsA is effective only at high-dose administration, which results in severe side effects such as seizure. Liposomal CsA showed significant suppression of inflammation and reduction of infarct size, and animals receiving liposomal CsA did not show obvious side effects.

As one part of the innate immunity, complement system is also activated in the ischemic brain. After the ischemia and reperfusion, injured neurons expressed complement component C1q, C3 and C5, microglia and astrocytes can also produce C1q and C3, which induces the phagocytosis of neurons by microglia through the interactions between C3b deposited on the neuronal surface and complement receptor three on microglia. Mice deficient in C3 were protected from reperfusion injury, which showed that inhibiting complement activation is a potential treatment method for stroke. To improve the efficiency of RNA interference, PEG-PLA NPs were applied to carry anti-complement C3 siRNA (C3-siRNA) with the assistance of cationic lipid, which is believed based on the electrostatic interactions. NPs that can deliver siRNA into the damaged brain and subsequently engulf by the microglia, and reduced the level of C3 in microglia and microglial neurotoxicity. Moreover, gene therapy with C3-siRNA-PEG-PLA-NPs decreased the infiltration of inflammatory cells and the level of pro-inflammatory mediators, and improved neurological outcomes.

5.6.2. Nanomedicines regulating inflammatory cells
As the resident immune cells in the brain, microglial cells are rapidly activated and then migrate to the damaged site under the action of DAMPs and chemokines. Although activated microglia are generally believed to exacerbate the damage, some studies have shown that unlike the classically activated M1-phenotype microglia with pro-inflammatory activity, alternatively activated M2-phenotype microglia could exert anti-inflammatory effects. In the peri-infarct region, newly recruited microglia are mainly M2-phenotype, but M1-phenotype gradually occupy main position to cause brain damage. Therefore, promoting the microglial polarization from M1 to M2 in the acute phase of stroke might be beneficial to reduce the inflammatory response at the lesion site.

The main pro-inflammatory cytokines secreted by M1 microglia are NF-κB-dependent, such as IL-1, IL-6, TNF-α, and regulating the NF-κB signaling pathway may promote the phenotypic transition from M1 to M2. Since NF-κB could also be activated by ROS, eliminating ROS might help achieve the phenotypic shift. For instance, PEGylated Ce-NPs can drive microglial polarization from M1 to M2 via scavenging multiple ROS, which is in favor of the resolution of inflammation and reduction of cell death. Nanomedicines have also been used to deliver small molecules to promote the phenotypic transition of microglia. Rapamycin could promote the microglia polarization from M1 to M2, yet the poor BBB permeability limits its application. Fibrin-binding peptide-modified micelles that contain ROS-sensitive phenylboronic ester units were applied to deliver rapamycin into the damaged brain. The modified micelles could realize higher retention in the thrombus site and subsequently accumulated in the ischemic brain. Micelles would collapse and release entrapped rapamycin response to the high-level ROS in the ischemic brain, which could protect neurons through eliminating ROS, and the liberated rapamycin would promote the phenotypic transition of microglia from M1 to M2, thereby inhibiting the damage of neurons and reducing the inflammation response (Fig. 5). The double-sided role of microglia reveals that the treatment of stroke should shift from simply inhibiting the activity of microglia to regulating the balance of cell phenotype.

5.6.3. Nanomedicines for pretreatment with TNF-α
Previous research has shown that patients with transient ischemic attack (TIA) preceding ischemic stroke had better neurological outcome, and this ischemic tolerance was related to the overexpression of TNF-α induced by TIA. Although TNF-α is generally considered to be a proinflammatory factor, pretreatment...
with TNF-α could also induce the production of anti-inflammatory mediators such as manganous superoxide dismutase through activating the NF-κB signaling pathway. Pretreatment with TNF-α significantly reduced the brain injury caused by following ischemia in mice, yet the half-life of TNF-α is short, which limits its application. PEG-b-(poly (ethylenediamine l-glutamate)-g-poly (l-lysine)) was applied to load negatively charged TNF-α via the electrostatic interactions, and the circulation time of TNF-α in vivo was prolonged. Preconditioned with TNF-α-loaded NPs to induce the ischemic tolerance would attenuate the oxidative stress damage and the inflammatory activity, and reduce the neuronal apoptosis level in the ischemic brain after reperfusion. Pre-treating to induce ischemic tolerance provides a new idea for the treatment of ischemic stroke, as for patients who have experienced TIA, pretreatment with effective nanomedicine might reduce the severity of following stroke.

5.7. Nanomedicines promoting tissue repair

Post-ischemic inflammation would subside gradually, and the damaged brain will undergo a structural and functional recovery process to return to homeostasis. Emerging evidences have shown that the resolution of inflammation is an active process benefiting from the action of anti-inflammatory mediators and immune cells. TGF-β and IL-10, two of the most important anti-inflammatory mediators, which are secreted in concert with the phagocytosis of dead cells, play a vital role in the establishment of anti-inflammatory microenvironment which is in favor of tissue...

Figure 5 (A) Schematic diagram of CPLB/RAPA micelle in modulating the damaged brain suffered from ischemia: 1) micelle bind the microthrombus through the interaction between fibrin and fibrin-binding peptide; 2) micelle accumulate in the ischemic brain via crossing the damaged BBB; 3) ROS initiate the release of rapamycin, rapamycin promote the phenotypic transition of microglia from M1 to M2, thereby inhibiting the damage of neurons and reducing the inflammation response. (B) Immunostaining of M1 (red) and M2 (green) microglia treatment with different formulations (scale bar = 50 μm). (C) Representative TTC staining images of ischemic brain from rats with different treatment. RAPA: rapamycin; PLB: PEG-phenylboronic ester modified polylysine; CPLB: fibrin-binding peptide CREKA modified PLB. Reprinted with the permission from Ref. 23. Copyright © 2019, WILEY-VCH.
repair\textsuperscript{147}. As M2 microglia are responsible for the phagocytosis to remove cell debris and the secretion of anti-inflammatory factors to restrict brain damage, the nanomedicines that regulate the microglial phenotype transition also helps brain tissue recovery after stroke\textsuperscript{63,62}.

GFs play a vital role in the development and survival of endothelial cells, glial cells and neurons\textsuperscript{148}. Ischemia would downregulate the level of GFs during the acute phase of stroke\textsuperscript{149}, which leads to neuron death, and treatment with GFs could protect brain against ischemic injury\textsuperscript{150–152}. Moreover, GFs also promoted the compensatory activation and differentiation of NSCs into specific brain cells, and the migration of NSCs to infarcted area, which is in favor of accelerating the recovery of cerebral function at the chronic phase of stroke\textsuperscript{153,154}. For instance, administration of nerve growth factor (NGF) promoted the proliferation of NSCs\textsuperscript{155}, and consecutive treatment enhanced striatal neurogenesis after stroke\textsuperscript{156,157}. APOE-modified human serum albumin NPs carrying NGF could assist the peptide penetrate into the damaged brain via the interaction between APOE and LRP1, and significantly promoted the brain recovery on two week post-stroke\textsuperscript{87}. Superparamagnetic iron oxide encapsulated in APOE-modified albumin NPs could enhance the outcome of magnetic resonance imaging, which could be applied to monitor the structural recovery of brain in real-time.

Recent studies have also shown that multiple microRNAs (miRNAs) are involved in the process of neuronal remodeling, and targeting delivery of miRNAs to mediate neurogenesis is expected to promote the prognosis after stroke\textsuperscript{158}. A study has indicated that viral vectors carrying miR-124 could promote angiogenesis in mice post-ischemia\textsuperscript{159}. However, viral vectors might induce the immune response \textit{in vivo}. Exosomes hold great promise as a gene delivery vector given their unique properties, including low immunogenicity, high delivery efficiency, and inherent ability to cross the BBB\textsuperscript{81}. Rabies virus glycoprotein-modified exosomes containing miR-124 could effectively transported miRNA into the ischemic area, and reduced the brain injury by promoting neural precursor cells in the infarcted area to differentiate into neurons\textsuperscript{88}. In another study, exosomes containing miR-17-92, obtained from the mesenchymal stromal cells transfected with miR-17-92-contained plasmids could cross the BBB, promote neurogenesis and axon growth, as well as functional recovery after stroke\textsuperscript{92}.

### Table 7

| Phase of cascade | Target | Nanomedicine and intervention strategy | Achievement | Limitation | Ref. |
|-----------------|--------|---------------------------------------|-------------|-----------|------|
| Inflammation    | Inhibiting pro-inflammatory mediators | Bypass the BBB | Intranasal delivery of e-PAM-R/anti-HMGB1 siRNA complex | Reduced the level of HMGB1 and suppressed the infarct volume | The safety of nasal administration needs further investigation | 97 |
|                 |        | Passively CsA-loaded liposomes | Suppressed inflammation and infarct volume | | The targeting efficiency need further improvement | 53 |
|                 |        | Passively Anti-complement C3 siRNA-loaded PEG-PLA NPs | Decreased the infiltration of inflammatory cells and the level of pro-inflammatory mediators | | Conjugating with targeting ligands might improve the treatment effect | 55 |
| Regulating inflammatory cells | Fibrin | PEGylated Ce-NPs | Drove microglial polarization from M1 to M2 | No experimental data \textit{in vivo} | | 139 |
| Pretreatment    | Passively | TNF-\(\alpha\)-loaded PEG-\(\beta\)-(PELG-g-PLL) NPs | Promoted the phenotypic transition of microglia from M1 to M2 | The side effects need further study | | 70 |
| Tissue repair   | LRP1 | NGF-loaded albumin NPs modified with APOE | Promoted the brain recovery on two weeks post-stroke | The effect of NPs in improving neurological deficits need further evaluation | | 87 |
| Biomimetic targeting | miR-124-loaded exosomes modified with rabies virus glycoprotein which could bind the nAChR on BBB | | Promoted neural precursor cells in the infarcted area to differentiate into neurons | Neuron-specific targeting ability needs further improvement | 88 |
| Biomimetic targeting | miR-17-92 contained exosomes derived from MSCs | | Promoted neurogenesis, axon growth and functional recovery | | 92 |
| Biomimetic targeting | Exosomes derived from MSCs | | Enhanced neuroprotection and nerve regeneration, improved neurovascular plasticity | | 162 |

MSCs, mesenchymal stromal cells; nAChR, nicotinic acetylcholine receptor.
Furthermore, exosomes separated from stem cell have been studied for their inherent powerful regenerative ability, as exosomes carry multiple proteins and genes that are related with tissue repair. A large number of evidences have shown that the MSC-derived exosomes possess numerous advantages in the treatment of stroke by enhancing neuroprotection and nerve regeneration, improving neurovascular plasticity, and promoting functional recovery. Therefore, exosomes originating from stem cells could not only deliver drugs to treat stroke, but also enhance the natural process of cerebral repair after injury induced by ischemia. Table 7 summarizes the strategies in targeted delivery of nanomedicines which could regulate multiple abnormalities.

5.8. Nanomedicine regulating multiple abnormalities

It is worth noting that various events of the ischemic cascade interact with each other. Upstream events will trigger downstream events, and downstream events will in turn amplify upstream events. Therefore, synergistic suppression of multiple abnormalities is expected to achieve better outcomes. Some drugs, such as curcumin, possess anti-oxidation, anti-apoptosis, and anti-inflammatory effects, and thus could simultaneously inhibit multiple abnormalities. In addition, there are many studies that integrated multiple agents with different functions into nanomedicine to realize combined therapy.

Furthermore, exosomes separated from stem cell have been studied for their inherent powerful regenerative ability, as exosomes carry multiple proteins and genes that are related with tissue repair. A large number of evidences have shown that the MSC-derived exosomes possess numerous advantages in the treatment of stroke by enhancing neuroprotection and nerve regeneration, improving neurovascular plasticity, and promoting functional recovery. Therefore, exosomes originating from stem cells could not only deliver drugs to treat stroke, but also enhance the natural process of cerebral repair after injury induced by ischemia. Table 7 summarizes the strategies in targeted delivery of nanomedicines which could regulate multiple abnormalities.

5.8. Nanomedicine regulating multiple abnormalities

It is worth noting that various events of the ischemic cascade interact with each other. Upstream events will trigger downstream events, and downstream events will in turn amplify upstream events. Therefore, synergistic suppression of multiple abnormalities is expected to achieve better outcomes. Some drugs, such as curcumin, possess anti-oxidation, anti-apoptosis, and anti-inflammatory effects, and thus could simultaneously inhibit multiple abnormalities. In addition, there are many studies that integrated multiple agents with different functions into nanomedicine to realize combined therapy.

For instance, nanoplatelets were developed to deliver alteplase and neuroprotectant ZL006. In detail, ZL006 was loaded in polymeric NP core, TAT-peptide-linked alteplase was conjugated on the surface of platelets membrane, and the linker could be cleaved by thrombin. NPs coated with platelets membrane retained the thrombus targeting ability of platelets, and released alteplase response to the highly expressed thrombin in clots. Then, the broken of the linker exposed the blocked TAT peptide, which promoted the penetration of NPs across the BBB to deliver ZL006. The combination of thrombolytics and neuroprotectant significantly reduced ischemia-related damage in MCAO rats.

In addition to combined treatment with thrombolytics and neuroprotective agents, inhibiting multiple stages of the ischemic
cascade is also a feasible method. Before reperfusion, hypoxia not only causes neuronal energy depletion, but also leads to the production of ROS; then reperfusion brings a boost of oxygen and leads to a large amount of ROS. T7-peptide-modified erythrocyte vesicles which contain Hb and manganous tetroxide NPs were developed to resolve this problem. The multifunctional vesicles showed superior O2 release capacity in the damaged brain before thrombolysis, and efficiently inhibited the boost of O2 after reperfusion, as Hb releases O2 under hypoxia and stores O2 in an oxygen-rich environment. In addition, manganous tetroxide NPs exhibited long-lasting scavenging ability against ROS. Regulating the level of O2 and ROS rescued ischemic brain before thrombolysis and after reperfusion30.

Moreover, polymer NPs with ROS-sensitive property are used to deliver drugs, which achieved antioxidant therapy through eliminating ROS, and realized combined therapy via carrying different drugs. For instance, glyburide-encapsulated betulenic acid NPs37, NR2B9c peptide-loaded boronic ester-modified dextran NPs38, and rapamycin-loaded boronic ester-modified polymer micelles39. The strategies, including achievement and limitation in targeted delivery of nanomedicine which could regulate multiple abnormalities are summarized in Table 8.

5.9. The response release of drug in the pathological site

For targeted delivery of nanomedicines, the release of the drug in response to the microenvironment of lesion could reduce the leakage of the drug in blood, increase the concentration of the drug at the targeting site, and reduce the administrated dosage and side effects. In the treatment of stroke, enzymes that are highly expressed in thrombus, such as thrombin, phospholipase A2, and ROS in ischemic brain tissue are often employed as stimulators of response release. Table 9 summarizes the nanomedicines which possess response release ability and the corresponding stimulators reviewed in this article.

6. Summary and prospect

Due to the lack of effective treatment method, the therapy and long-term recovery of ischemic stroke remains a main challenge for doctors and patients. Recently, nanomedicines have been widely used in the treatment of stroke, as it improved the therapeutical effect of traditional drugs and provided possibilities for the realization of emerging therapies, such as gene therapy50. Nanomedicines for targeted delivery of thrombolytics and neuroprotectant have also exhibited good results in preclinical research.

It is worth mentioning that the ischemic cascade events occur at different intervals and interacts with each other40. Therefore, a great number of nanomedicines have shown functions against multiple pathological events at different stages of the cascade reaction41,2,25. In theory, intervening the upstream events of ischemic cascade should be suitable for the treatment of stroke, yet some upstream events occur very quickly, even if the interventions were carried out within one or 2 h after ischemic attack, the damage caused by aforementioned events is still difficult to reverse completely42. Thus, nanomedicines targeting downstream events of ischemic cascade such as oxidative stress, inflammation response, and tissue repair might be more promising in the treatment of stroke32,38.

The properties of nanocarrier, including particle size, shape, hydrophilic characteristics and surface charge would affect the fate of nanomedicines in vivo. For instance, normally, the half-life of negatively charged NPs in vivo is longer, since positively charged NPs tend to absorb proteins such as opsonin in blood. PEGylation would enhance the hydrophilicity of NPs and reduce the opsonizing effect of opsonin, which further reduces the phagocytosis of RES and extends the circulation time of nanomedicine.

In addition, the unique pathophysiological environment of the body will also affect the fate of particles. After ischemia and reperfusion, the integrity of the BBB is destroyed and the permeability increases, nanomedicines could accumulate in the brain through the damaged BBB. Non-targeted nanomedicine might mainly accumulate in the ischemic core where the BBB is disturbed more seriously50,118, which is not conducive to the rescue of ischemic penumbra. In order to improve the permeability of the BBB, BBB modulators were adopted to temporarily open the tight junction to allow more NPs to penetrate into the brain. The long-term safety of this method still needs further investigation, as excessive opening of the BBB will increase the risk of hemorrhagic transformation.

Modifying nanomedicines with specific ligands through covalent conjugation or electrostatic interaction would further increase the accumulation of NPs in the brain through receptor-mediated transcytosis. After stroke, multiple receptors are highly expressed on BBB, which provides new opportunities for the targeted delivery of nanomedicine78,30,84. It is worth noting that targeted nanomedicine modified with endogenous ligand may encounter competition with endogenous ligand in the blood when passing through the BBB, which reduces the targeting efficiency. Fortunately, antibodies with stronger specificity to receptors have been developed, and the interactions are not affected by endogenous ligands.

Among numerous nanomedicines, liposomes, micelles, and polymeric NPs are mainly investigated due to their mature preparation technology, with the hope of translation into clinical application. Although inorganic NPs have favorable uniformity and are easy to be industrialized, the safety needs further serious investigation if used in human. In recent years, biomimetic nanomedicines, based on living cells or cell membrane vesicles/exosomes, have provided new opportunities for drug targeting delivery. The unique biocompatibility and safety, and inherent targeting properties promote them as a research hotspot of nanomedicines for targeted treatment of stroke, with the expectation of bringing new breakthroughs in stroke treatment31. As the development of new carrier and deeper understanding of pathological mechanisms, nanomedicines are casting new lights in stroke treatment.

Acknowledgments

We acknowledge the support from the International Cooperative project of the National Key R&D Program of China (Grant No. 2017YFE0126900), National Natural Science Foundation of China (Grant No. 81872808), Program of Shanghai Academic Research Leader (18XD1400500,China) and Shanghai Municipal Science and Technology Major Project (No.2018SHZDZX01, China) and ZJ Lab.

Author contributions

Chao Li composed the article under the guidance of Tao Sun and Chen Jiang.
Conflicts of interest

The authors have no conflicts of interest to declare.

References

1. Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, et al. Heart disease and stroke statistics—2020 update: a report from the American Heart Association. Circulation 2020;141:e139–96.

2. Sacco RL, Kasner SE, Broderick JP, Caplan LR, Connors JJ, Culebras A, et al. An updated definition of stroke for the 21st century: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2013;44:2064–89.

3. Kaszewska B, Wardlaw JM, Marshall I, Cvrbo V, Wirtolowska K, Haga K, et al. Early brain temperature elevation and anaerobic metabolism in human acute ischaemic stroke. Brain 2009;132:955–64.

4. Castillo J, Loza Mi, Mirelman D, Brea J, Blanco M, Sobrino T, et al. A novel mechanism of neuroprotection: blood glutamate grabber. J Cerebr Blood Flow Metabol 2016;36:292–301.

5. Lewén A, Matz P, Chan PH. Free radical pathways in CNS injury. J Neurotrauma 2000;17:871–90.

6. Chan PH. Reactive oxygen radicals in signaling and damage in the ischemic brain. J Cerebr Blood Flow Metabol 2001;21:2–14.

7. Gürsoy-Ozdemir Y, Bolay H, Saribas’ O, Dalkara T. Role of endo- thelial nitric oxide generation and peroxynitrite formation in reperfusion injury after focal cerebral ischemia. Stroke 2000;31:1974–80.

8. Peerschke EI, Yin W, Ghebrehiwet B. Platelet activation on platelets: implications for vascular inflammation and thrombosis. Mol Immunol 2010;47:2170–5.

9. Peerschke EI, Reid KB, Ghebrehiwet B. Platelet activation by C1q results in the induction of alpha IIbbeta3 integrins (GPIIb-IIIa) and the expression of P-selectin and procoagulant activity. J Exp Med 1993;178:579–87.

10. Huang J, Kim LJ, Mealey R, Marsh Jr HC, Zhang Y, Tenner AJ, et al. Neuronal protection in stroke by an sLex-glycosylated complement inhibitory protein. Science 1999;285:595–9.

11. Mocco J, Mack WJ, Ducrot AF, Sosunov SA, Sughrue ME, Hassid BG, et al. Complement component C3 mediates inflammatory injury following focal cerebral ischemia. Circ Res 2006;99:209–17.

12. Brown GC, Neher JJ. Microglial phagocytosis of live neurons. Rev Neurosci 2000;11:579–87.

13. Iadecola C, Anrather J. The immunology of stroke: from mechanisms to translation. Nat Med 2011;17:796–808.

14. Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2019;50:e344–418.

15. Hacke W, Donnan G, Fieschi C, Kaste M, Kummer R, Broderick JP, et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004;363:768–74.

16. Frank B, Grotta JC, Alexandrov AV, Bluhmki E, Lyden P, Meretoja A, et al. Thrombolysis in stroke despite contraindications or warnings?. Stroke 2013;44:727–33.

17. Peters O, Back T, Lindauar U, Busch C, Megow D, Dreier J, et al. Increased formation of reactive oxygen species after permanent and reversible middle cerebral artery occlusion in the rat. J Cerebr Blood Flow Metabol 1998;18:196–205.

18. Allen CL, Bayraktutan U. Oxidative stress and its role in the pathogenesis of ischaemic stroke. Int J Stroke 2009;4:661–70.

19. Kevil CG, Oshima T, Alexander B, Cee LL, Alexander JS. H2O2-mediated permeability: role of MAPK and occludin. Am J Physiol Cell Physiol 2000;279:C21–30.

20. Kelly PJ, Morrow JD, Ning MM, Korseshet W, Lo EH, Terry E, et al. Oxidative stress and matrix metalloproteinase-9 in acute ischemic stroke: the biomarker evaluation for antioxidant therapies in stroke (BEAT-Stroke) study. Stroke 2008;39:100–4.

21. Chamorro A, Dintagl U, Ufra X, Planas AM. Neuroprotection in acute stroke: targeting excitotoxicity, oxidative and nitrosative stress, and inflammation. Lancet Neurol 2016;15:869–81.

22. O’Collins VE, Macleod MR, Donnan GA, Horky LL, Worp BH, Howells DW, et al. 1,026 experimental treatments in acute stroke. Ann Neurol 2006;59:467–77.

23. Lu YF, Li C, Chen QJ, Liu PX, Guo Q, Zhang Y, et al. Microthrombus-targeting micelles for neurovascular remodeling and enhanced microcirculatory perfusion in acute ischemic stroke. Adv Mater 2019;31:e1808361.

24. Han L, Li JF, Huang SX, Huang RQ, Liu SH, Hu X, et al. Peptide-conjugated polyamidoamine dendrimer as a nanoscale tumor-targeted T1 magnetic resonance imaging contrast agent. Biomaterials 2011;32:2989–98.

25. Fabian RH, DeWitt DS, Kent TA. In vivo detection of superoxide anion production by the brain using a cytochrome c electrode. J Cerebr Blood Flow Metabol 1995;15:242–7.

26. Yamato M, Egashira T, Utsumi H. Application of in vivo ESR spectroscopy to measurement of cerebrovascular ROS generation in stroke. Free Radic Biol Med 2003;35:1619–31.

27. Melani A, Turchi D, Vanacucchi MG, Ciripiani S, Gianfriddo M, Pedata F. ATP extracellular concentrations are increased in the rat striatum during in vivo ischemia. Neurochem Int 2005;47:442–8.

28. Bours MJ, Swennen EL, Virgilio FD, Cronstein BN, Dagnelie PC. Adenosine 5'-triphosphate and adenosine as endogenous signaling molecules in immunity and inflammation. Pharmacol Ther 2006;112:358–404.

29. Marsh BJ, Williams-Karnesky RL, Zentzel-Poore MP. Toll-like receptor signaling in endogenous neuroprotection and stroke. Neuroscience 2009;158:1007–20.

30. Harari OA, Liao JK. NF-kB and innate immunity in ischemic stroke. Ann N Y Acad Sci 2010;1207:32–40.

31. Sandoval KE, Witt KA. Blood–brain barrier tight junction permeability and ischemic stroke. Neurobiol Dis 2008;32:200–19.

32. Huang J, Upadhyay UM, Tamargo RJ. Inflammation in stroke and focal cerebral ischemia. Surg Neurol 2006;66:232–45.

33. Yamasaki Y, Matsu Y, Matsura N, Onodera H, Itoyama Y, Kogure K. Transient increase of cytokine-induced neutrophil chemoattractant, a member of the interleukin-8 family, in ischemic brain areas after focal ischemia in rats. Stroke 1995;26:318–22.

34. Minami M, Satoh M. Chemokines and their receptors in the brain: pathophysiological roles in ischemic brain injury. Life Sci 2003;74:321–7.

35. Wang X, Yue TL, Barone FC, Feuerstein GZ. Monocyte chemo-attractant protein-1 messenger RNA expression in rat ischemic cerebral cortex following focal ischemia. J Cerebr Blood Flow Metabol 1995;15:242–7.

36. Heo JH, Han SW, Lee SK. Free radicals as triggers of brain edema after focal cerebral ischemia. J Cerebr Blood Flow Metabol 1998;18:196–205.
39. Mackman N. Triggers, targets and treatments for thrombosis. *Nature* 2008;451:914–8.
40. Mega JL, Simon T. Pharmacology of antithrombotic drugs: an assessment of oral antplatelet and anticoagulant treatments. *Lancet* 2015;386:281–91.
41. Sandercop PA, Counsell C, Kane EJ. Anticoagulants for acute ischaemic stroke. *Cochrane Database Syst Rev* 2015;2015.Cd000024.
42. Tanswell P, Modi N, Combs D, Danays T. Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic therapy of acute myocardial infarction. *Clin Pharmacokinet* 2002;41:1229–45.
43. Campbell BCV, Mitchell PJ, Churilov L, Yassi N, Kleing TJ, Dowling RJ, et al. Tenecteplase versus alteplase before thrombectomy for ischaemic stroke. *N Engl J Med* 2018;378:1573–82.
44. Mediclli RL. Desmoteplase: discovery, insights and opportunities for ischaemic stroke. *Br J Pharmacol* 2012;165:75–89.
45. Trotman M, Vermeeren P, Gibson CL, Fern R. The dichotomy of memantine treatment for ischaemic stroke: dose-dependent protective and detrimental effects. *J Cereb Blood Flow Metabol* 2015;35:230–9.
46. Horn J, Haan RJ, Vermeulen M, Limburg M. Nimodipine in animal model experiments of focal cerebral ischemia: a systematic review. *Stroke* 2001;32:2433–8.
47. Amemiya S, Kamiya T, Nito C, Inaba T, Kato K, Ueda M, et al. Anti-apoptotic and neuroprotective effects of edaravone following transient focal ischemia in rats. *Eur J Pharmacol* 2005;516:125–30.
48. Edaravone Acute Infarction Study Group. Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction. Randomized, placebo-controlled, double-blind study at multicenters. *Cerebrovasc Dis* 2003;15:222–9.
49. Huang J, Choudhi TF, Wintree CJ, McGartag RA, Kiss S, Mocco J, et al. Postischemic cerebrovascular E-selectin expression mediates tissue injury in murine stroke. *Stroke* 2000;31:3047–53.
50. Fu Y, Zhang NN, Ren L, Yan YP, Sun N, Li YJ, et al. Impact of an immune modulator fingolimod on acute ischemic stroke. *Proc Natl Acad Sci U S A* 2014;111:18315–20.
51. Wang XY, Tsuji K, Lee SR, Ning MM, Furie KL, Buchan AM, et al. Selective liposomal transport through blood brain barrier and detrimental effects. *Brain Pathol* 2015;25:248.
52. Edaravone Acute Infarction Study Group. Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction. Randomized, placebo-controlled, double-blind study at multicenters. *Cerebrovasc Dis* 2003;15:222–9.
53. Partoazar A, Nasoohi S, Rezayat SM, Gilani K, Mehr SE, Amani A, et al. Emerging paradigms for ischemic stroke. *Br J Pharmacol* 2012;165:75–89.
54. Kaviarasi S, Yuba E, Harada A, Krishnan UM. Oxidants, antioxidants and neuronal damage in transient middle cerebral artery occlusion rats. *Front Pharmacol* 2018;9:1403.
55. Wang Y, Luo J, Li SY. Nano-curcumin simultaneously protects the blood–brain barrier and reduces M1 microglial activation during cerebral ischemia–reperfusion injury. *Acps Appl Mater Interfaces* 2019;11:3763–70.
56. Kim ID, Lim CM, Kim JB, Nam HY, Nam K, Kim SW, et al. Treatment of stroke with liposomal neuroprotective agents under cerebral ischemia conditions. *Eur J Pharm Biopharm* 2015;97:1–7.
57. Xu HE, Hua Y, Zhong J, Li XL, Xu W, Cai YY, et al. Resveratrol delivery by albumin nanoparticles improved neurological function and neuronal damage in transient middle cerebral artery occlusion rats. *Front Pharmacol* 2018;9:723–32.
58. Fukuta T, Ishii T, Asai T, Sato A, Kikuchi T, Shimizu K, et al. Anti-edema and antioxidant combination therapy for ischemic stroke via glyburide-loaded betulinic acid nanoparticles. *Theranostics* 2019; 9:6991–7002.
59. Al-Ahmadieh ZS, Jasim D, Ahmad SS, Wong R, Haley M, Coutts G, et al. Selective liposomal transport through blood–brain barrier disruption in ischemic stroke reveals two distinct therapeutic opportunities. *ACS Nano* 2019;13:12470–86.
96. Kalani A, Chaturvedi P, Kamal PD, Maldonado C, Bauer P, Joshua IG, et al. Curcumin-loaded embryonic stem cell exosomes restored neurovascular unit following ischemia–reperfusion injury. Int J Biochem Cell Biol 2016;79:360–9.

97. Kim ID, Shin JH, Kim SW, Choi S, Ahn J, Han PL, et al. Intranasal delivery of HMGB1 siRNA confers target gene knockdown and robust neuroprotecton in the postischemic brain. Mol Ther 2012;20:829–39.

98. Harston GW, Okell TW, Sheerin F, Schulz U, Mathieson P, Reckless I, et al. Quantification of serial cerebral blood flow in acute stroke using arterial spin labeling. Stroke 2017;48:123–30.

99. Jin HQ, Tan H, Zhao LL, Sun WP, Zhu LJ, Sun YA, et al. Ultrasound-triggered thrombolysis using urokinase–loaded nanogels. Int J Pharm 2012;434:384–90.

100. Teng YM, Jin HQ, Nan D, Li MN, Fan CH, Liu YY, et al. In vivo evaluation of urokinase–loaded hollow nanogels for sonothrombolysis on suture embolization–induced acute ischemic stroke rat model. Bioact Mater 2018;3:102–9.

101. Yurko Y, Maximov V, Andreozzi E, Thompson GL, Vertegel AA. Design of biomedical nanodevices for dissolution of blood clots. Mater Sci Eng C 2009;29:737–41.

102. Vaidya B, Nayak MK, Dash D, Agrawal GP, Vyas SP. Development and characterization of site specific target sensitive liposomes for the delivery of thrombolytic agents. Int J Pharm 2011;403:254–61.

103. Vaidya B, Agrawal GP, Vyas SP. Platelets directed liposomes for the delivery of streptokinase: development and characterization. Eur J Pharm Sci 2011;44:589–94.

104. Vaidya B, Nayak MK, Dash D, Agrawal GP, Vyas SP. Development and characterization of highly selective target-sensitive liposomes for the delivery of streptokinase: in vitro and in vivo studies. Drug Deliv 2016;23:801–7.

105. Pawlowski CL, Li W, Sun M, Ravichandran K, Hickman D, Kos C, et al. Platelet microparticle-inspired clot-responsive nanomedicine for targeted fibrinolysis. Biomaterials 2017;128:94–108.

106. Saxena R, Wijnhoud AD, Carton H, Hacke W, Kaste M, Przybelski RJ, et al. Controlled safety study of a hemoglobin-based oxygen carrier, DCLHb, in acute ischemic stroke. Stroke 1999;30:993–6.

107. Bobofchak KM, Mito T, Texel SJ, Bellelli A, Nemoto M, Trastajman RJ, et al. A recombinant polymorphic hemoglobin with conformational, functional, and physiological characteristics of an in vivo O2 transporter. Am J Physiol Heart Circ Physiol 2003;285:H549–61.

108. Kawaguchi AT, Fukushima D, Haida M, Ogata Y, Yamano M, Tsukada H. Liposome-encapsulated hemoglobin reduces the size of cerebral infarction in the rat: evaluation with photochemically induced thrombosis of the middle cerebral artery. Stroke 2007;38:1626–32.

109. Fukushima D, Kawaguchi AT, Haida M, Yamano M, Ogata Y, Tsukada H. Liposome-encapsulated hemoglobin reduces the size of cerebral infarction in rats: effect of oxygen affinity. Artif Organs 2009;33:159–63.

110. Hamadate N, Yamaguchi T, Sugawara A, Togashi H, Izumi T, Yoshida T, et al. Liposome-encapsulated hemoglobin ameliorates impairment of fear memory and hippocampal dysfunction after cerebral ischemia in rats. J Pharmacol Sci 2010;114:409–19.

111. Komatsu H, Funuya T, Sato N, Ohita K, Matsuura A, Ohmura T, et al. Effect of hemoglobin vesicle, a cellular-type artificial oxygen carrier, on middle cerebral artery occlusion- and arachidonic acid-induced stroke models in rats. Neurosci Lett 2007;421:121–5.

112. Simard JM, Chen MK, Tarasov KV, Bhatta S, Ivanova S, Melnitchenko L, et al. Newly expressed SUR1-regulated NCx (Na-Ca-ATP) channel mediates cerebral edema after ischemic stroke. Nat Med 2006;12:433–40.

113. Simard JM, Sheth KN, Kimberly WT, Stern BJ, Zoppo GJ, Jacobson S, et al. Glibenclamide in cerebral ischemia and stroke. Neurocrit Care 2014;20:319–33.

114. Persak M, Badjatia N, Chaturvedi S, Cronin CA, Kimberly WT, Sheth KN, et al. BIB093 (IV glibenclamide): an investigational compound for the prevention and treatment of severe cerebral edema. Exp Opin Invest Drugs 2019;28:1031–40.
115. Tournier N, Saba W, Cisternino S, Peyronneau MA, Damont A, Goutal S, et al. Effects of selected OATP and/or ABC transporter inhibitors on the brain and whole-body distribution of glyburide. AAPS J 2013;15:1082–90.

116. Zhou L, Li F, Xu HB, Luo CX, Wu HY, Zhu MM, et al. Treatment of cerebral ischemia by disrupting ischemia-induced interaction of nNOS with PSD-95. Nat Med 2010;16:1439–43.

117. Liu SH, Guo YB, Huang RQ, Li JF, Huang SX, Kuang YY, et al. Gene and doxorubicin co-delivery for targeting therapy of glioma. Biomaterials 2012;33:4907–16.

118. Ishii T, Asai T, Oyama D, Agato Y, Yasuda N, Fukuta T, et al. Treatment of cerebral ischemia–reperfusion injury with PEGylated liposomes encapsulating FK506. FASEB J 2013;27:1362–70.

119. Cao YG, Mao XY, Sun CY, Zheng P, Gao JQ, Wang XR, et al. Gene and doxorubicin co-delivery for targeting therapy of glioma. Biomaterials 2012;33:4907–16.

120. Doggui S, Sahni JK, Arseneault M, Dao L, Ramassamy C. Neuronal uptake and neuroprotective properties of curcumin-loaded PLGA nanoparticles on the human SK-N-SH cell line. J Alzheimer’s Dis 2012;30:377–92.

121. Doggui S, Zaghmi A, Safar R, Dao L, Reisch A, et al. Neuronal uptake and neuroprotective effect of curcumin-loaded PLGA nanoparticles on the human SK-N-SH cell line. J Alzheimer’s Dis 2012;30:377–92.

122. Djokeng Paka G, Doggui S, Zaghmi A, Safar R, Dao L, Reisch A, et al. Neuronal uptake and neuroprotective properties of curcumin-loaded nanoparticles on SK-N-SH cell line: role of poly(lactide-co-glycolide) polymeric matrix composition. Mol Pharm 2016;13:391–403.

123. Qiu JF, Guo X, Wang BL, Wei WX, Guo ML, Men K, et al. Preparation and characterization of monomethoxy poly(ethylene glycol)-poly(ε-caprolactone) micelles for the solubilization and in vivo delivery of luteolin. Int J Nanomed 2013;8:3061–9.

124. Yoshitomi T, Suzuki R, Mamiya T, Matsui H, Hirayama A, Nagasaki Y. pH-sensitive radical-containing nanoparticle (RNP) for the L-band-EPR imaging of low pH circumstances. Bioconjugate Chem 2009;20:1792–8.

125. Yoshitomi T, Miyamoto D, Nagasaki Y. Design of core-shell-type nanoparticles carrying stable radicals in the core. Bio-macromolecules 2009;10:596–601.

126. Kinouchi H, Epstein CJ, Mizui T, Carlson E, Chen SF, Chan PH. Attenuation of focal cerebral ischemic injury in transgenic mice overexpressing CuZn superoxide dismutase. Proc Natl Acad Sci U S A 1991;88:6153–62.

127. Armogida M, Spalloni A, Amantea D, Nutini M, Petrelli F, Longone P, et al. The protective role of catalase against cerebral ischemia in vitro and in vivo. Int J Immunopathol Pharmacol 2011;24:735–47.

128. Reddy MK, Labhasetwar V. Nanoparticle-mediated delivery of superoxide dismutase to the brain: an effective strategy to reduce ischemia–reperfusion injury. FASEB J 2009;23:1384–95.

129. Huang X, Ding J, Li YF, Liu WJ, Ji JL, Wang H, et al. Exosomes derived from PDEF modified adipose-derived mesenchymal stem cells ameliorate cerebral ischemia–reperfusion injury by regulation of autophagy and apoptosis. Exp Cell Res 2018;371:269–77.

130. Siret AL, Fratelli M, Brines M, Goemans C, Casagrande S, Lewczuk P, et al. Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci U S A 2001;98:4044–9.

131. Erbayraktar S, Grasso G, Sfakteria A, Xie QW, Coleman T, Kreilgaard M, et al. Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo. Proc Natl Acad Sci U S A 2003;100:6741–6.

132. Sanchez A, Tripathy D, Yin X, Luo J, Martinez J, Grammas P. Pigment epithelium-derived factor (PEDF) protects cortical neurons in vitro from oxidative injury by activation of extracellular signal-regulated kinase (ERK) 1/2 and induction of BCL-2. Neurosci Res 2012;72:1–8.

133. Wang Q, Gou XC, Xiong LZ, Jin WL, Chen SY, Hou LC, et al. Trans-activator of transcription-mediated delivery of NEPI1–40 protein into brain has a neuroprotective effect against focal cerebral ischemic injury via inhibition of neuronal apoptosis. Anesthiology 2008;108:1071–80.

134. Chamorro A, Meisel A, Planas AM, Urra X, Beek DV, Veltkamp R. The immunology of acute stroke. Nat Rev Neurol 2012;8:401–10.

135. Castillo J, Moro MA, Blanco M, Leira R, Serena J, Lizasoain J, et al. The release of tumor necrosis factor-alpha is associated with ischemic tolerance in human stroke. Ann Neurol 2003;54:811–9.

136. Zhao SC, Ma LS, Chu ZH, Xu H, Wu WQ, Liu FD. Regulation of microglial activation in stroke. Acta Pharmacol Sin 2017;38:445–58.

137. Xia CY, Zhang S, Gao Y, Wang ZZ, Chen NH. Selective modulation of microglia polarization to M2 phenotype for stroke treatment. Int Immunopharm 2015;25:377–82.

138. Hu XM, Li PY, Guo XL, Wang HY, Leak RK, Chen S, et al. Microglia/macrophage polarization dynamics reveal novel mechanism of injury expansion after focal cerebral ischemia. Stroke 2012;43:3063–70.

139. Zeng F, Wu YW, Li XW, Guo QH, Lou XB, et al. Custom-made ceria nanoparticles show a neuroprotective effect by modulating phenotypic polarization of the microglia. Angew Chem Int Ed Engl 2018;57:5808–12.

140. Wong GH, Goeddel DV. Induction of manganese superoxide dismutase by tumor necrosis factor: possible protective mechanism. Science 1988;242:941–4.

141. Hallenbeck JM. The many faces of tumor necrosis factor in stroke. Nat Med 2002;8:1363–8.

142. Ginis I, Jaiswal R, Klimanis D, Liu J, Greenspoon J, Hallenbeck JM. TNF-alpha-induced tolerance to ischemic injury involves differential control of NF-kappaB transactivation: the role of NF-kappaB association with p300 adaptor. J Cereb Blood Flow Metab 2002;22:142–52.

143. Nawashiro H, Tasaki K, Ruetzler CA, Hallenbeck JM. TNF-alpha pretreatment induces protective effects against focal cerebral ischemia in mice. J Cereb Blood Flow Metab 1997;17:483–90.

144. Spite M, Serhan CN. Novel lipid mediators promote resolution of acute inflammation: impact of aspirin and statins. Circ Res 2010;107:1170–84.

145. Schilling M, Besselmann M, Müller M, Strecker JK, Ringelstein EB, Kiefer R. Predominant phagocytic activity of resident microglia over hematogenous macrophages following transient focal cerebral ischemia: an investigation using green fluorescent protein transgenic bone marrow chimeric mice. Exp Neurol 2005;196:290–7.

146. Davalos D, Grutzendler J, Yang G, Kim JV, Zuo Y, Jung S, et al. ATP mediates rapid microglial response to local brain injury in vivo. Nat Neurosci 2005;8:752–8.

147. Nathan C, Ding AH. Nonresolving inflammation. Cell 2010;140:871–82.

148. Abe K. Therapeutic potential of neurotrophic factors and neural stem cells against ischemic brain injury. J Cereb Blood Flow Metab 2000;20:1393–408.

149. Lee TH, Kato H, Chen ST, Kogure K, Itoyama Y. Expression of nerve growth factor and trkA after transient focal cerebral ischemia in rats. Stroke 1998;29:1687–96.

150. Holtzman DM, Sheldon RA, Jaffe W, Cheng Y, Ferriero DM. Nerve growth factor protects the neonatal brain against hypoxic-ischemic injury. Ann Neurol 1998;43:114–22.

151. Shigeno T, Mima T, Takakura K, Graham DI, Kato G, Hashimoto Y, et al. Erythropoietin prevents neuronal apoptosis after focal cerebral ischemia in vivo. J Cereb Blood Flow Metab 1998;19:1124–30.

152. Kitagawa H, Hayashi T, Matsuura Y, Koga N, Itoyama Y, Abe K. Reduction of ischemic brain injury by topical application of gical cell line-derived neurotrophic factor after permanent middle cerebral artery occlusion in rats. Stroke 1998;29:1417–22.

153. Takagi Y, Nozaki K, Takahashi J, Yodoi J, Ishikawa M, Hashimoto N. Proliferation of neuronal precursor cells in the dentate gyrus is accelerated after transient forebrain ischemia in mice. Brain Res 1999;831:283–7.
154. Craig CG, Tropepe V, Morshead CM, Reynolds BA, Weiss S, Kooy DV. In vivo growth factor expansion of endogenous subependymal neural precursor cell populations in the adult mouse brain. J Neurosci 1996;16:2649—58.

155. Zhao Y, Xie P, Zhu XF, Cai ZY. Neural stem cell transplantation and nerve growth factor promote neurological recovery in rats with ischemic stroke. Nan Fang Yi Ke Da Xue Xue Bao 2008;28:1123—6.

156. Zhu WS, Cheng SM, Xu GL, Ma MM, Zhou ZM, Liu DZ, et al. Intranasal nerve growth factor enhances striatal neurogenesis in adult rats with focal cerebral ischemia. Drug Deliv 2011;18:338—43.

157. Rhim T, Lee M. Targeted delivery of growth factors in ischemic stroke animal models. Expert Opin Drug Deliv 2016;13:709—23.

158. Liu XS, Chopp M, Zhang RL, Zhang ZG. MicroRNAs in cerebral ischemia-induced neurogenesis. J Neuropathol Exp Neurol 2013;72:718—22.

159. Doepnner TR, Doehring M, Bretschneider E, Zechariah A, Kaltwasser B, Müller B, et al. MicroRNA-124 protects against focal cerebral ischemia via mechanisms involving Usp14-dependent REST degradation. Acta Neuropathol 2013;126:251—65.

160. Xin HQ, Li Y, Chopp M. Exosomes/miRNAs as mediating cell-based therapy of stroke. Front Cell Neurosci 2014;8:377.

161. Shi JJ, Yu WY, Xu LH, Yin N, Liu W, Zhang XX, et al. Bioinspired nanosponge for salvaging ischemic stroke via free radical scavenging and self-adapted oxygen regulating. Nano Lett 2020;20:780—9.

162. Otero-Ortega L, Gómez de Frutos MC, Laso-García F, Rodríguez-Frutos B, Medina-Gutiérrez E, López JA, et al. Exosomes promote restoration after an experimental animal model of intracerebral hemorrhage. J Cerebr Blood Flow Metabol 2018;38:767—79.

163. Lipton P. Ischemic cell death in brain neurons. Physiol Rev 1999;79:1431—568.